Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Rapid Infusion of Dinutuximab for Neuroblastoma
Recruiting5 awardsPhase 4
Los Angeles, California
This trial is testing whether the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab can be given to children with high-risk neuroblastoma over four hours or less, which would allow for administration of this immunotherapy agent in the outpatient setting.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.